|
[1]
|
Handbook of Neurodegenerative Disorders
2023
DOI:10.1007/978-981-19-3949-5_20-1
|
|
|
|
|
[2]
|
A mechanistic review of pharmacological activities of homeopathic medicine licorice against neural diseases
Frontiers in Neuroscience,
2023
DOI:10.3389/fnins.2023.1148258
|
|
|
|
|
[3]
|
An Interplay Between Post-Traumatic Epilepsy and Associated Cognitive Decline: A Systematic Review
Frontiers in Neurology,
2022
DOI:10.3389/fneur.2022.827571
|
|
|
|
|
[4]
|
Aquaporin 4 in Traumatic Brain Injury: From Molecular Pathways to Therapeutic Target
Neurochemical Research,
2022
DOI:10.1007/s11064-021-03512-w
|
|
|
|
|
[5]
|
Disulfide HMGB1 acts via TLR2/4 receptors to reduce the numbers of oligodendrocyte progenitor cells after traumatic injury in vitro
Scientific Reports,
2021
DOI:10.1038/s41598-021-84932-0
|
|
|
|
|
[6]
|
Disulfide HMGB1 acts via TLR2/4 receptors to reduce the numbers of oligodendrocyte progenitor cells after traumatic injury in vitro
Scientific Reports,
2021
DOI:10.1038/s41598-021-84932-0
|
|
|
|
|
[7]
|
HMGB1, neuronal excitability and epilepsy
Acta Epileptologica,
2021
DOI:10.1186/s42494-021-00048-y
|
|
|
|
|
[8]
|
Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside
Metabolic Brain Disease,
2021
DOI:10.1007/s11011-021-00806-4
|
|
|
|
|
[9]
|
Effect of folinic acid on serum homocysteine, TNFα, IL-10, and HMGB1 gene expression in head injury model
Annals of Medicine and Surgery,
2021
DOI:10.1016/j.amsu.2021.102273
|
|
|
|
|
[10]
|
Potential Neuroprotective Effect of the HMGB1 Inhibitor Glycyrrhizin in Neurological Disorders
ACS Chemical Neuroscience,
2020
DOI:10.1021/acschemneuro.9b00640
|
|
|
|
|
[11]
|
Potential Neuroprotective Effect of the HMGB1 Inhibitor Glycyrrhizin in Neurological Disorders
ACS Chemical Neuroscience,
2020
DOI:10.1021/acschemneuro.9b00640
|
|
|
|
|
[12]
|
Elucidating the novel biomarker and therapeutic potentials of High-mobility group box 1 in Subarachnoid hemorrhage: A review
AIMS Neuroscience,
2019
DOI:10.3934/Neuroscience.2019.4.316
|
|
|
|
|
[13]
|
HMGB1: A Common Biomarker and Potential Target for TBI, Neuroinflammation, Epilepsy, and Cognitive Dysfunction
Frontiers in Neuroscience,
2018
DOI:10.3389/fnins.2018.00628
|
|
|
|
|
[14]
|
High-mobility group box 1 is a promising diagnostic and therapeutic monitoring biomarker in Cancers: A review
AIMS Molecular Science,
2018
DOI:10.3934/molsci.2018.4.183
|
|
|
|
|
[15]
|
Myeloid-derived Suppressor Cells in Cancer: A Review on the Pathogenesis and Therapeutic Potentials
The Open Cancer Immunology Journal,
2018
DOI:10.2174/1876401001807010016
|
|
|
|
|
[16]
|
Epochal neuroinflammatory role of high mobility group box 1 in central nervous system diseases
AIMS Molecular Science,
2017
DOI:10.3934/molsci.2017.2.185
|
|
|
|
|
[17]
|
Pivotal neuroinflammatory and therapeutic role of high mobility group box 1 in ischemic stroke
Bioscience Reports,
2017
DOI:10.1042/BSR20171104
|
|
|
|